BACKGROUND AND OBJECTIVES: Colorectal cancer (CRC) arising in patients under age 30 is a rare disease, and few cases have been reported within Li-Fraumeni kindreds. To determine how often alterations in the p53 pathway genes contribute to disease susceptibility, we have evaluated patients with early onset CRC for the presence of germline variants in the p53 gene and MDM2 SNP309. METHODS: Thirty-five patients with CRC diagnosed before age 30 were included in this study-based on tissue availability. DNA samples from peripheral blood leukocytes were analyzed for constitutional mutations and polymorphisms in p53 as well as polymorphisms in MDM2 SNP309. RESULTS: No mutations were found in exons 4-10 of the p53 gene. The frequencies of polymorphisms in p53 and in MDM2 SNP309 did not differ from rates previously reported for normal control populations, and no polymorphism in either gene could be associated with early onset CRC. CONCLUSIONS: Neither germline variants in p53 nor MDM2 SNP309 play an underlying role in the development of very early onset CRC. For the large majority of cases, the genetic basis of this disease remains unknown.
BACKGROUND AND OBJECTIVES:Colorectal cancer (CRC) arising in patients under age 30 is a rare disease, and few cases have been reported within Li-Fraumeni kindreds. To determine how often alterations in the p53 pathway genes contribute to disease susceptibility, we have evaluated patients with early onset CRC for the presence of germline variants in the p53 gene and MDM2 SNP309. METHODS: Thirty-five patients with CRC diagnosed before age 30 were included in this study-based on tissue availability. DNA samples from peripheral blood leukocytes were analyzed for constitutional mutations and polymorphisms in p53 as well as polymorphisms in MDM2 SNP309. RESULTS: No mutations were found in exons 4-10 of the p53 gene. The frequencies of polymorphisms in p53 and in MDM2 SNP309 did not differ from rates previously reported for normal control populations, and no polymorphism in either gene could be associated with early onset CRC. CONCLUSIONS: Neither germline variants in p53 nor MDM2 SNP309 play an underlying role in the development of very early onset CRC. For the large majority of cases, the genetic basis of this disease remains unknown.
Authors: G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg Journal: J Med Genet Date: 2005-10-28 Impact factor: 6.318
Authors: Gareth L Bond; Kim M Hirshfield; Tomas Kirchhoff; Gabriella Alexe; Elisabeth E Bond; Harlan Robins; Frank Bartel; Helge Taubert; Peter Wuerl; William Hait; Deborah Toppmeyer; Kenneth Offit; Arnold J Levine Journal: Cancer Res Date: 2006-05-15 Impact factor: 12.701
Authors: J Groden; A Thliveris; W Samowitz; M Carlson; L Gelbert; H Albertsen; G Joslyn; J Stevens; L Spirio; M Robertson Journal: Cell Date: 1991-08-09 Impact factor: 41.582
Authors: Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano Journal: Cancer Cell Date: 2010-09-14 Impact factor: 31.743
Authors: Marianne Berg; Stine A Danielsen; Terje Ahlquist; Marianne A Merok; Trude H Ågesen; Morten H Vatn; Tom Mala; Ole H Sjo; Arne Bakka; Ingvild Moberg; Torunn Fetveit; Øystein Mathisen; Anders Husby; Oddvar Sandvik; Arild Nesbakken; Espen Thiis-Evensen; Ragnhild A Lothe Journal: PLoS One Date: 2010-11-12 Impact factor: 3.240